Clinical Trial of Heart Failure Drug Underway Soon

(Yale School of Medicine/Wikimedia Commons)

Cardioxyl Pharmaceuticals Inc. in Chapel Hill, North Carolina, today announced the start of clinical trial of its lead drug candidate, CXL-1020, for the treatment of acute decompensated heart failure (ADHF). The trial will help define proper dosing for the drug.

Cardioxyl’s placebo-controlled phase 2-a trial will take place in as many as 20 sites in the U.S. and overseas. The study will enroll 54 to 66 cardiac patients with decompensated heart failure and will evaluate hemodynamic factors during intravenous infusion of CXL-1020 at several dose levels. Investigators will assess these factors with invasive and non-invasive techniques including both echocardiography and direct Swan-Ganz catheter-based measures of heart pressures and function. The study will also expand the database of safety information for CXL-1020.

ADHF is the leading diagnosis for patients at the time of discharge from U.S. hospitals and the most common cause of hospitalization for patients over 65 years of age.